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Chediak-Higashi Syndrome is a rare genetic disease. 
The clinical features include oculocutaneous albinism, 
immunodeficiency, neurological manifestations, mild 





Phenotype and clinics 
The symptoms of CHS patients are variable. They have 
highly variable hypopigmentation of the skin, eye and 
hair (oculocutaneus albinism). The Neurological 
manifestations are also variable, including cognitive 
impairment, peripheral neuropathy, ataxia, and 
parkinsonism. In addition, the CHS patients have 
frequent infections, particularly bacterial infections of 
the skin and respiratory tract. Symptoms can appear 
anytime from childhood to early adulthood. Generally 
speaking, CHS patients have mild coagulation defects 
including epistaxis, gum/mucosal bleeding, and easy 
bruising. 
The accelerated phase, which occurs in 85% of 
individuals with CHS, can take place at any age. 
Clinical manifestations include fever, 
lymphadenopathy, hepatosplenomegaly, anemia, 
neutropenia, and sometimes thrombocytopenia.  
Originally thought to be a malignancy resembling 
lymphoma, the accelerated phase is now known to be a 
hemophagocytic lymphohistiocytosis characterized by 
multiorgan inflammation.  
The accelerated phase and its complications are the 
most common causes of mortality in CHS patients. 
Most CHS patients present in early childhood and die 
unless treated by bone marrow transplantation. About 
10-15% of patients exhibit a much milder clinical 
symptoms and survive to adulthood, but develop 
progressive and often fatal neurological dysfunction.  
Very rare patients exhibit an intermediate adolescent 
CHS phenotype, with severe infections in early 
childhood, but a milder course by adolescence, and no 
accelerated phase. 
Treatment 
Infections are treated with antibiotics. Antiviral drugs 
such as acyclovir and chemotherapy drugs are often 
used in the accelerated phase of the disease. Surgery 
may be needed to drain abscesses in some cases. 
Patients in the accelerated phase are treated with 
chemoimmunotherapy followed by transition to 
continuation therapy. Allogenic HSCT is the only 
treatment to cure hematologic and immunologic 
defects. Platelet transfusions are needed for serious 
bleeding. Corrective lenses help to improve visual 
acuity. Treatment by rehabilitation specialists areus d 
for neurologic complications. 
Prognosis 
CHS patients usually die in their first decade of life, 
from chronic infections or accelerated disease. 
However, some mildly affected children have survived 
longer. 
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Figure 1. The structure and mutations of the human LYST gene. Filled box indicate coding sequences. Hatched box indicate 5' and 3' 
untranslated sequences. Left-hatched indicates 5' untranslated sequences in mRNA containing exons 1 and 3, right-hatched indicates 5' 
untranslated sequences in mRNAs containing exon 2, and double- hatched indicates common 5' and 3' untranslated sequences. E1 and 
E2 represent mutually exclusive 5' terminal exons, and corresponding alternative promoters are indicated by right-facing arrows. Filled 
diamonds denote frameshifts, filled triangles denote nonsense mutations, and filled circles denote missense substitutions. (Katrim et al., 
2002). 
 






55 exons spanning 205.9 kb of genomic DNA. 
Transcription 
Two alternative transcriptions.  
The large transcript (12.0 kb) produces functional 
protein.  







Figure 2. A schematic representation of motifs found in 
CHS protein. (Ward et al., 2000). 
Description 
The CHS protein is composed of 3801 amino acids. 
The molecular weight of the CHS protein is 430 kDa. 
The N-terminus of the protein has a large stretch of 
alpha-helices termed HEAT repeats (Figure 2). HEAT 
repeats are important to mediate membrane 
associations and are associated with vesicle transport.  
The C-terminus of the protein has two domains that are 
conserved between the human and mouse homologues.  
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The first of these domains has been referred to as the 
BEACH domain. The BEACH domain contains a 
consensus 'WIDL' amino acid stretch as well as several 
other conserved amino acids that define members of the 
CHS protein family. The second domain contains a 
WD-40 repeat region, indicative of a protein-protein 
interaction domain. 
Expression 




Lysosome trafficking regulator. 
Homology 
There are 82% identity and 88% homology between the 
human and mouse proteins. Similar degrees of identity 
are seen among human, rat and cow CHS genes. 
Mutations 
Note 
More than 50 mutations have been identified, most of 
which are nonsense mutations that result in premature 
stop codons and thus a truncated protein. Figure 1 
shows the distribution of the mutations. 
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